Susceptibility-Related Cytokine Panel for Prediction of Polygonum multiflorum-Induced Hepatotoxicity in Humans
Open Access
- 1 March 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Inflammation Research
- Vol. ume 14, 645-655
- https://doi.org/10.2147/jir.s299892
Abstract
Background: Drug-induced liver injury is a common adverse effect in clinical practice, with severe cases resulting in liver failure and even death. Identification and prediction of individuals susceptible to idiosyncratic DILI continues to remain a challenge. Methods: In this study, we report that cytokines in human serum can be used to identify and predict individuals susceptible to Polygonum multiflorum-induced DILI (PM-DILI) in retrospective and prospective cohort studies. Findings: In the retrospective pilot study, we compared serum cytokine expression profiles of the PM-DILI group (n=10) and the PM-Tolerant group (n=12) and found 10 cytokines with significant differences. In the replication cohort study, differences in the 10 cytokines between PM-DILI (n =11) and PM-Tolerant (n=13) groups were verified. Among them, 6 cytokines showed no significant differences at two time points, including liver injury and recovery stage of PM-DILI, suggesting that these 6 cytokines have no correlation with PM-DILI, however, they may be related to susceptibility. Furthermore, all the retrospective cohorts were combined, and a PM-DILI susceptibility prediction model was built by screening the 6 cytokines. The combination of (TNF-α and CCL-2) or VEGF showed the highest sensitivity and specificity. Finally, the efficacy of the above 3 cytokine combination models in predicting PM-DILI-susceptible individuals was verified before PM exposure in another independent prospective cohort (n=24), with sensitivity and specificity of 66.7% and 83.3%, respectively. Conclusion: This proof-of-concept study demonstrates that the serum cytokine combination reflecting dysimmunity could be used as a new method to predict PM-DILI, thus providing a new perspective for improving the clinical management of IDILI.Keywords
This publication has 30 references indexed in Scilit:
- Drug-induced liver injuryNature Reviews Disease Primers, 2019
- Drug-Induced Liver Injury — Types and PhenotypesThe New England Journal of Medicine, 2019
- Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factorJournal of Hepatology, 2017
- HLA-DRB1*16Pharmacogenetics and Genomics, 2016
- Drug-induced liver injury: Interactions between drug properties and host factorsJournal of Hepatology, 2015
- ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver InjuryThe American Journal of Gastroenterology, 2014
- Review article: drug‐induced liver injury in clinical practiceAlimentary Pharmacology & Therapeutics, 2010
- HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinNature Genetics, 2009
- Drug-Related HepatotoxicityThe New England Journal of Medicine, 2006
- Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicityJournal of Hepatology, 2004